logo
Plus   Neg
Share
Email

FDA Approves First Generic Version Of Epilepsy Drug Sabril

The U.S. Food and Drug Administration has approved the first generic version of Sabril (vigabatrin) for treatment of complex partial seizures. The generic version of Sabril is manufactured by Teva Pharmaceutical Industries (TEVA).

"Prioritizing the approval of generic drugs to compete with medicines that face little or no competition is a key part of our efforts to support access and reduce drug costs to patients. The availability of high-quality generic alternatives of critically important medicines, once the period of patent protection or exclusivity has ended on the brand drug, helps advance access and saves consumers billions of dollars each year," said FDA Commissioner Scott Gottlieb, M.D.

Complex partial seizures, a common type of seizures, start in a specific area of the brain and can affect consciousness. Typically, complex partial seizures last between 30 and 90 seconds, and are often followed by a period of disorientation, confusion and/or fatigue.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Target Corp. has introduced Everspring, a new household essentials brand comprised of more than 70 household essentials items that includes bio-based or recycled materials or natural fibers. The new, in-house brand has been designed by Target with sustainability in mind and is part of its efforts to make products that include ingredients derived from plants or renewable materials more accessible. While reporting financial results for the first quarter, American Express Co. (AXP) on Thursday affirmed its earnings and revenue growth guidance for the full-year 2019. For fiscal 2019, the company continues to project earnings in the range of $7.64 to $8.14 per share and adjusted earnings in the... While reporting financial results for the first quarter, Honeywell international Inc. (HON) on Thursday raised its earnings and sales outlook for the full-year 2019. For fiscal 2019, the company raised its earnings outlook to a range of $7.90 to $8.15 per share from the previous guidance range of...
Follow RTT